Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study.

MLA

Bouman, Karlijn, et al. “Natural History, Outcome Measures and Trial Readiness in LAMA2-Related Muscular Dystrophy and SELENON-Related Myopathy in Children and Adults: Protocol of the LAST STRONG Study.” BMC Neurology, vol. 21, no. 1, Aug. 2021, p. 313. EBSCOhost, https://doi.org/10.1186/s12883-021-02336-z.

APA

Bouman, K., Groothuis, J. T., Doorduin, J., van Alfen, N., Udink Ten Cate, F. E. A., van den Heuvel, F. M. A., Nijveldt, R., van Tilburg, W. C. M., Buckens, S. C. F. M., Dittrich, A. T. M., Draaisma, J. M. T., Janssen, M. C. H., Kamsteeg, E.-J., van Kleef, E. S. B., Koene, S., Smeitink, J. A. M., Küsters, B., van Tienen, F. H. J., Smeets, H. J. M., … Voermans, N. C. (2021). Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study. BMC Neurology, 21(1), 313. https://doi.org/10.1186/s12883-021-02336-z

Chicago

Bouman, Karlijn, Jan T Groothuis, Jonne Doorduin, Nens van Alfen, Floris E A Udink Ten Cate, Frederik M A van den Heuvel, Robin Nijveldt, et al. 2021. “Natural History, Outcome Measures and Trial Readiness in LAMA2-Related Muscular Dystrophy and SELENON-Related Myopathy in Children and Adults: Protocol of the LAST STRONG Study.” BMC Neurology 21 (1): 313. doi:10.1186/s12883-021-02336-z.